Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Liposarcoma 1Diabetes Mellitus, Type 2 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Troglitazone × Clear all
NCT00003058 2017-02-13

Troglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed
85 enrolled
Sarcoma

Liposarcoma, Sarcoma

NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡